December 8, 2025BloodOpen Access

Comparable efficacy of CR, CRh, and CRi in pediatric acute myeloid leukemia: A report from the Japan Children's Cancer Group

View Full Paper

Ask AI

Bookmark

Authors

KNKaori NiwaMie University YMYoko MizoguchiHiroshima University KHKeizo HoribeNational Hospital Organization

Discussion

Member takes

Implication

Analysis of survival and treatment outcomes in pediatric acute myeloid leukemia shows comparable efficacy of CRh and CRi versus CR, indicating ongoing needs for optimal therapy.

Key Points

Survival outcomes were comparable among CRh and CRi compared to complete remission in acute myeloid leukemia.
Five-year event-free survival was 63.4% for complete remission, with no significant differences for CRh and CRi.
Analysis of two nationwide multicenter clinical trials revealed similar response patterns for pediatric patients.
MRD monitoring may provide further insight as a surrogate endpoint of pediatric acute myeloid leukemia treatment.

Cite This Study

Niwa et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e571 https://doi.org/10.1182/blood-2025-3512

View Full Paper

Ask AI

Bookmark

Implication

Analysis of survival and treatment outcomes in pediatric acute myeloid leukemia shows comparable efficacy of CRh and CRi versus CR, indicating ongoing needs for optimal therapy.

Comparable efficacy of CR, CRh, and CRi in pediatric acute myeloid leukemia: A report from the Japan Children's Cancer Group

Discussion

Member takes

Implication

Key Points

Cite This Study

Comparable efficacy of CR, CRh, and CRi in pediatric acute myeloid leukemia: A report from the Japan Children's Cancer Group

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider